Disclosures for "Long COVID Brain Fog Treatment: Feasibility Metrics from An Early-phase Randomized Controlled Trial of Constraint-Induced Cognitive Therapy"
-
The institution of Dr. Agnihotri has received research support from Roche/ Genentech.
-
Prof. Uswatte has stock in GE. Prof. Uswatte has stock in Several companies. For example I won stock in Google. I am sure they have some health care products but I have no idea for certain or what they. That's probably true of every stock I own.. The institution of Prof. Uswatte has received research support from NIH. The institution of Prof. Uswatte has received research support from NIDILRR.
-
Dr. Ball has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Posit Science. Dr. Ball has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Posit Science. Dr. Ball has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Ageing and Longevity. Dr. Ball has stock in Visual Awareness Research Group. Dr. Ball has received intellectual property interests from a discovery or technology relating to health care.
-
Mr. Mitchell has nothing to disclose.
-
Mr. Blake has nothing to disclose.
-
Mrs. Mckay has nothing to disclose.
-
The institution of Dr. Biney has received research support from NIH.
-
Ms. Iosipchuk has nothing to disclose.
-
Ms. Hempfling has nothing to disclose.
-
Mrs. Harris has nothing to disclose.
-
Dr. Dickerson has nothing to disclose.
-
Dr. Lokken has nothing to disclose.
-
Dr. Knight has nothing to disclose.
-
Dr. Mark has nothing to disclose.
-
Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel Incorporated, Medimmune/Viela Bio, Medday, Merck/Serono, Neurogenesis LTD, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion/Cerexis Pharmaceuticals, Regeneron, Reckover Pharmaceuticals, Roche, TG Therapeutics.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Applied Therapeutics, AI therapeutics, AMO Pharma, Astra-Zeneca, Avexis Pharmaceuticals, Biolinerx, Brainstorm Cell Therapeutics, Bristol Meyers Squibb/Celgene, CSL Behring, Galmed Pharmaceuticals, Green Valley Pharma, Horizon Pharmaceuticals, Immunic, Karuna Therapeutics, Mapi Pharmaceuticals LTD, Merck, Mitsubishi Tanabe Pharma Holdings, Opko Biologics,Prothena Biosciences, Novartis, Regeneron, Sanofi-Aventis, Reata Pharmaceuticals, NHLBI (Protocol Review Committee), University of Texas Southwestern, University of Pennsylvania, Visioneering Technologies, Inc.. Dr. Cutter has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.